#1 Clinical Trials Search in Europe

Wt1/Il15/Il15Ra Mrna Dc

A groundbreaking clinical trial is underway to evaluate a novel cancer vaccine called WT1/IL15/IL15Ra mRNA DC. This vaccine is designed to target advanced or refractory solid tumors of the pancreas, esophagus, liver, or ovaries. The study aims to assess the safety, feasibility, and potential effectiveness of this innovative immunotherapy approach in patients who have limited treatment options.

Table of Contents

What is WT1/IL15/IL15RA mRNA DC?

WT1/IL15/IL15RA mRNA DC is an experimental cancer vaccine being studied for the treatment of advanced or refractory solid tumors[1]. This innovative therapy belongs to a class of treatments called dendritic cell vaccines, which are designed to stimulate the body’s immune system to fight cancer cells[1].

How Does It Work?

The vaccine is created using a patient’s own cells, making it a personalized treatment. Here’s a simplified explanation of how it works:

  1. Doctors collect certain immune cells (monocytes) from the patient’s blood through a process called leukapheresis[1].
  2. These cells are then transformed into dendritic cells in the laboratory. Dendritic cells are important because they help activate other immune cells to recognize and attack cancer[1].
  3. The dendritic cells are then modified with special genetic instructions (mRNA) that tell them to produce three important components:
    • WT1 (Wilms’ Tumor 1): A protein often found in cancer cells[1].
    • IL15 (Interleukin 15): A substance that helps stimulate immune cells[1].
    • IL15RA (Interleukin 15 Receptor alpha): A component that helps IL15 work more effectively[1].
  4. The modified dendritic cells are then given back to the patient through an injection under the skin (intradermal injection)[1].

Once in the body, these specially engineered cells are designed to activate the patient’s immune system to recognize and attack cancer cells that have the WT1 protein[1].

Target Conditions

This experimental treatment is being studied for patients with advanced or refractory solid tumors, specifically in the following organs[1]:

  • Pancreas
  • Esophagus
  • Liver
  • Ovaries

The treatment is intended for patients whose cancer has progressed after at least one previous treatment or for whom no standard therapy is available or suitable[1].

Clinical Trial Details

The WT1/IL15/IL15RA mRNA DC vaccine is currently being studied in a Phase I/II clinical trial. This means it’s in the early stages of testing in humans[1]. The main goals of this trial are:

  1. To evaluate if it’s feasible to produce and administer the vaccine[1].
  2. To assess the safety of the treatment[1].
  3. To look for early signs of effectiveness against the cancer[1].
  4. To measure how well the vaccine stimulates the immune system[1].
  5. To understand how the treatment affects patients’ quality of life[1].

Eligibility Criteria

Not all patients with the target cancers will be eligible for this trial. Some key eligibility criteria include[1]:

  • Age 18 or older
  • Confirmed diagnosis of an advanced solid tumor in the pancreas, esophagus, liver, or ovaries
  • Cancer that has progressed after at least one previous treatment, or no standard treatment options available
  • Reasonable life expectancy of at least 3 months
  • Good overall health status (WHO performance status 0-2)

Patients with certain conditions, such as autoimmune diseases or who are pregnant or breastfeeding, may not be eligible for the trial[1].

Potential Benefits

While it’s important to remember that this is an experimental treatment and its effectiveness is not yet proven, the researchers hope to see the following potential benefits[1]:

  • Shrinkage or stabilization of tumors
  • Longer time before the cancer progresses
  • Improved overall survival
  • Better quality of life for patients

Safety and Side Effects

As this is a new treatment, all possible side effects are not yet known. The clinical trial will closely monitor patients for any adverse events (side effects) that may occur during and after treatment[1]. The safety of the vaccine is one of the main things being studied in this trial.

It’s important for patients to discuss potential risks and benefits with their healthcare team before considering participation in this or any clinical trial[1].

Aspect Details
Study Type Phase I/II clinical trial
Treatment WT1/IL15/IL15Ra mRNA DC vaccine
Administration Intradermal injection
Target Conditions Advanced or refractory solid tumors of pancreas, esophagus, liver, or ovaries
Primary Objectives Feasibility and safety assessment
Secondary Objectives Clinical efficacy indicators, immunogenicity, quality of life changes
Key Eligibility Criteria Age ≥18, advanced/refractory solid tumors, prior treatment or no standard options available
Main Exclusion Criteria Recent use of investigational agents, active autoimmune disease, pregnancy or breastfeeding

FAQ

  • What is WT1/IL15/IL15Ra mRNA DC? WT1/IL15/IL15Ra mRNA DC is a type of cancer vaccine made from a patient's own dendritic cells. These cells are modified to express a tumor-associated protein called WT1 and molecules that help stimulate the immune system (IL15 and IL15Ra).
  • Who is eligible for this clinical trial? The trial is open to patients aged 18 and older with advanced, recurrent, or progressing solid tumors of the pancreas, esophagus, liver, or ovaries. Participants must have already received at least first-line anti-cancer treatment or have no other standard therapy options available.
  • How is the vaccine administered? The WT1/IL15/IL15Ra mRNA DC vaccine is given through intradermal injection, which means it's injected just beneath the skin.
  • What are the main goals of this clinical trial? The primary objectives are to evaluate the feasibility and safety of producing and administering the vaccine. Secondary goals include assessing potential clinical effectiveness, studying the immune response generated by the vaccine, and monitoring changes in patients' quality of life.
  • What kind of side effects might be expected? As this is a first-in-human study, the full range of potential side effects is not yet known. The trial will closely monitor for any adverse events (AEs) and serious adverse events (SAEs) related to the vaccine. Patients will be regularly assessed for safety throughout the study.

Ongoing Clinical Trials on Wt1/Il15/Il15Ra Mrna Dc

  • Study on WT1/IL15/IL15Ra mRNA DC Vaccine for Patients with Advanced or Refractory Solid Tumors of the Pancreas, Esophagus, Liver, or Ovaries

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Dendritic cells (DCs): Immune cells that help stimulate an immune response against specific targets, such as cancer cells.
  • WT1 (Wilms' Tumor 1): A protein often found in higher amounts in certain types of cancer cells, making it a potential target for cancer treatments.
  • IL15 (Interleukin 15): A molecule that helps stimulate and maintain certain types of immune cells, potentially enhancing the immune response against cancer.
  • IL15Ra (Interleukin 15 Receptor alpha): A component that works with IL15 to improve its ability to activate immune cells.
  • mRNA: Messenger RNA, a type of genetic material that carries instructions for making proteins. In this vaccine, mRNA is used to instruct dendritic cells to produce specific proteins.
  • Leukapheresis: A procedure to collect white blood cells from a patient's blood, used in this study to obtain the cells needed to create the personalized vaccine.
  • Intradermal injection: A method of delivering a substance just beneath the skin.
  • Adverse Events (AEs): Any unfavorable or unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it's related to the treatment being studied.
  • Serious Adverse Events (SAEs): Adverse events that result in hospitalization, disability, or are life-threatening.
  • iRECIST criteria: Immune-related Response Evaluation Criteria in Solid Tumors, a set of guidelines used to assess how tumors respond to immunotherapy treatments.

References

  1. http://clinicaltrials.eu/trial/study-on-wt1-il15-il15ra-mrna-dc-vaccine-for-patients-with-advanced-or-refractory-solid-tumors-of-the-pancreas-esophagus-liver-or-ovaries/